Welireg (belzutifan)

pCPA File Number: 22455

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Sponsor/Manufacturer:

Merck Canada Inc.

CADTH Project Number:

PC0309

pCPA Engagement Letter Issued:

2023-12-07

Negotiation Process Concluded:

Not Applicable